Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

Phase 3 Active not recruiting 77 enrolled Pfizer

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This Master Protocol for Avelumab Continuation Sub-Studies is to provide continued treatment access, safety follow-up, and when applicable, overall survival follow-up for eligible participants who continue to derive a benefit from study intervention in the Pfizer-sponsored Avelumab parent studies.

Timeline

Start: 2021-09-29
Primary completion: 2026-12-31
Completion: 2026-12-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Avelumab	Monoclonal antibody	—	Oral
Subject	Axitinib	Small molecule	—	Oral
Subject	Ivuxolimab	Monoclonal antibody	—	Intravenous
Subject	Lorlatanib	Unknown	—	Oral
Subject	Pemetrexed	Small molecule	—	Intravenous
Subject	Talazoparib	Small molecule	—	Oral
Subject	Utomilumab	Monoclonal antibody	—	Intravenous
Subject	Vidutolimod	Other / unclassified	—	Other

Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

Summary

Timeline

Drugs

Indications